目的 探討西黃膠囊聯(lián)合莫西沙星治療慢性盆腔炎的臨床療效。方法 回顧性選取2022年3月—2024年1月北京市懷柔區(qū)婦幼保健院中醫(yī)科收治的76例慢性盆腔炎患者，根據(jù)用藥方案差異將患者分為對照組（38例）和治療組（38例）。對照組口服鹽酸莫西沙星片，0.4 g/次，每日1次。在對照組基礎(chǔ)上，治療組口服西黃膠囊，8粒/次，每日2次。1個療程為7 d，兩組治療3個療程。觀察治療療效和臨床癥狀緩解時間，比較兩組治療前后簡明健康生活質(zhì)量狀況調(diào)查表評分（SF-36）、女性性功能指數(shù)評分（FSFI）、盆腔包塊直徑大小、白細胞介素1β（IL-1β）、基質(zhì)金屬蛋白酶-2（MMP-2）、細胞間黏附分子-1（ICAM-1）、血管內(nèi)皮生長因子（VEGF）水平。結(jié)果 治療21 d后，治療組總有效率是94.74%，顯著高于對照組的76.32%（P＜0.05）。治療21 d后，治療組下腹墜痛緩解時間、神疲乏力緩解時間、白帶增多緩解時間、腰骶酸痛緩解時間均顯著短于對照組（P＜0.05）。治療后，兩組患者FSFI評分、SF-36評分顯著升高，而盆腔包塊直徑明顯縮?。?i>P＜0.05）；治療后，與對照組對比，治療組FSFI評分、SF-36評分均高于對照組，盆腔包塊直經(jīng)小于對照組（P＜0.05）。治療后，兩組MMP-2、ICAM-1、IL-1β、VEGF水平均顯著降低（P＜0.05）；治療后，與對照組對比，治療組MMP-2、ICAM-1、IL-1β、VEGF水平均更低（P＜0.05）。結(jié)論 西黃膠囊與莫西沙星協(xié)同治療療效顯著，能縮短患者癥狀緩解時間，縮小盆腔包塊直徑，減弱機體炎性反應(yīng)，有效提升生活質(zhì)量，值得臨床借鑒。

Objective To investigate the therapeutic effect of Xihuang Capsules combined with moxifloxacin in treatment of chronic pelvic inflammatory disease. Methods 76 Patients with chronic pelvic inflammatory disease admitted to the Department of Traditional Chinese Medicine of Huairou District Maternal and Child Health Hospital of Beijing from March 2022 to January 2024 were retrospectively selected. According to the difference of medication regimen, the patients were divided into control (38 cases) and treatment (38 cases). Patients in control were po administered with Moxifloxacin Hydrochloride Tablets, 0.4 g/time, once daily. Patients in treatment were po administered with Xihuang Capsules on the basis of the control, 8 grains/time, twice daily. 7 Days was a course of treatment, and patients in both were treated for 3 consecutive courses. The therapeutic effect and clinical symptom remission time were observed. The levels of IL-1β, MMP-2, ICAM-1, and VEGF were compared between two before and after treatment. Results After 21 d of treatment, the total effective rate of the treatment was 94.74%, which was significantly higher than that of the control (76.32%, P < 0.05). After 21 d of treatment, the relief time of lower abdominal pain, fatigue, leucorrhea and lumbosacral pain in the treatment were significantly shorter than those in the control (P< 0.05). After treatment, FSFI scores and SF-36 scores were significantly increased in both, but the diameter of pelvic mass was significantly reduced (P < 0.05). After treatment, compared with the control, FSFI score and SF-36 score in the treatment were higher than those in the control, and the direct length of pelvic mass was lower than that in the control group (P < 0.05). After treatment, the levels of MMP-2, ICAM-1, IL-1β and VEGF were significantly decreased in both (P < 0.05). After treatment, the levels of MMP-2, ICAM-1, IL-1β and VEGF in the treatment were lower than those in the control (P < 0.05). Conclusion Xihuang Capsules combined with moxifloxacin has a good clinical effect in treatment of chronic pelvic inflammatory disease, and can shorten the symptom relief time of patients, reduce the diameter of pelvic mass and the inflammatory response of the body.

R984

首都醫(yī)科附屬北京婦產(chǎn)醫(yī)院懷柔婦幼保健院東方育苗科研基金（FYDY2023-04）